JPMorgan Chase & Co. Cuts Vera Therapeutics (NASDAQ:VERA) Price Target to $96.00

Vera Therapeutics (NASDAQ:VERA) had its target price lowered by JPMorgan Chase & Co. from $99.00 to $96.00 in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

VERA has been the topic of a number of other reports. HC Wainwright reiterated a “buy” rating and issued a $90.00 price objective on shares of Vera Therapeutics in a report on Friday, November 28th. TD Cowen lifted their price target on shares of Vera Therapeutics from $60.00 to $73.00 and gave the company a “buy” rating in a research note on Friday, December 5th. Pivotal Research set a $73.00 price objective on shares of Vera Therapeutics in a research note on Friday, December 5th. Wedbush lifted their target price on Vera Therapeutics from $23.00 to $33.00 and gave the company a “neutral” rating in a research report on Thursday, December 11th. Finally, Cowen reiterated a “buy” rating on shares of Vera Therapeutics in a report on Friday, December 5th. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Vera Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $74.83.

Vera Therapeutics Stock Performance

Shares of Vera Therapeutics stock opened at $51.22 on Friday. The firm has a market cap of $3.27 billion, a price-to-earnings ratio of -12.84 and a beta of 1.21. The stock’s 50-day moving average is $33.89 and its 200-day moving average is $27.25. Vera Therapeutics has a one year low of $18.53 and a one year high of $51.72. The company has a debt-to-equity ratio of 0.19, a current ratio of 12.21 and a quick ratio of 12.21.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.06). During the same period last year, the company posted ($0.85) earnings per share. Equities analysts predict that Vera Therapeutics will post -2.89 earnings per share for the current fiscal year.

Insider Activity

In other news, SVP Joseph R. Young sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $29.06, for a total value of $435,900.00. Following the completion of the sale, the senior vice president directly owned 47,839 shares of the company’s stock, valued at $1,390,201.34. This trade represents a 23.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Patrick G. Enright acquired 5,882 shares of the business’s stock in a transaction dated Thursday, December 11th. The stock was acquired at an average cost of $42.50 per share, with a total value of $249,985.00. Following the completion of the transaction, the director owned 5,882 shares of the company’s stock, valued at approximately $249,985. The trade was a ? increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 16.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in VERA. Quantbot Technologies LP acquired a new stake in Vera Therapeutics during the 2nd quarter valued at $51,000. Quarry LP raised its position in shares of Vera Therapeutics by 25.0% in the first quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $60,000 after purchasing an additional 500 shares during the period. AlphaQuest LLC lifted its stake in shares of Vera Therapeutics by 404.7% during the 1st quarter. AlphaQuest LLC now owns 4,007 shares of the company’s stock worth $96,000 after buying an additional 3,213 shares during the last quarter. Virtus Investment Advisers LLC boosted its holdings in shares of Vera Therapeutics by 14.8% during the 2nd quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock worth $98,000 after buying an additional 539 shares during the period. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Vera Therapeutics by 192.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock worth $99,000 after buying an additional 2,757 shares during the period. 99.21% of the stock is owned by institutional investors and hedge funds.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.